Eli Lilly’s Obesity Pill Shows Promising Weight Loss in New Results
1 min read
Summary
Pharmaceutical company Eli Lilly has announced that an experimental pill it has produced for the treatment of obesity has yielded promising results in initial trials, with participants in the highest dose group losing an average of 12% of their body weight.
The drug, called orforglipron, is a once-daily pill in the same class as the company’s popular anti-obesity injection Zepbound and the diabetes treatments Ozempic and Wegovy.
During the 18-month trial, more than 3000 adults with an average starting weight of 228 lb (103 kg) and a BMI of 37 (considered obese) were randomly assigned to receive 6, 12 or 36mg of orforglipron or a placebo.
The company plans to submit orforglipron for regulatory approval by the end of the year.
